Next Generation Vector Engineering and Delivery Topic: From ex vivo complexity to in vivo delivery: what will it take to manufacture lentiviral vectors for the next generation of cell therapy?
08 Sept 2026
Gene Therapy Development
- How is the rise of in vivo CAR-T changing expectations for lentiviral vector design, quality, and scalability?
- What vector attributes matter most for in vivo use: tropism, potency, integration profile, particle quality, impurity profile, or dose efficiency?
- Where do current LV manufacturing platforms need to evolve to support higher-volume, repeatable, injectable in vivo products?
- What analytical methods and release assays will be needed to connect vector quality to in vivo performance?
- How early should developers engage manufacturing partners when vector engineering choices may determine future scalability?
